Drug class
Low-molecular-weight heparinoid; antithrombin-dependent anti-factor Xa anticoagulant
Mechanism of action
Enhances antithrombin-mediated inhibition of factor Xa and, to a lesser extent, thrombin. It has a low cross-reactivity with platelet factor 4 antibodies compared with heparin, making it an option in selected heparin-induced thrombocytopenia settings.
General use cases
- Prevention and treatment of venous thromboembolism in patients with heparin-induced thrombocytopenia (HIT) or at risk of HIT in countries where danaparoid is authorised; use requires specialist anticoagulation monitoring
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
